Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CTSA | P10619 | 1/20 | 0.50 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | TDO2 | P48775 | 1/20 | 0.44 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.43 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 1/20 | 0.42 |
| ▸ | FNTB | P49356 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SI | P14410 | 1/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5721007 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2KMT2ACTSAANPEPENPEP | |
| SCHEMBL31295274 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2KMT2ACTSAANPEPENPEP | |
| SCHEMBL29478418 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2KMT2ACTSAANPEPENPEP | |
| SCHEMBL21459503 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2KMT2ACTSAANPEPENPEP | |
| SCHEMBL31295271 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2KMT2ACTSAANPEPENPEP | |
| SCHEMBL38666095 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2KMT2ACTSAANPEPENPEP | |
| Hydrochloric Acid SCHEMBL28252684 | 0.98 | SMN1; SMN2 (0.54) | SMN1; SMN2KMT2ACTSAANPEPENPEP | |
| SCHEMBL7141329 | 0.82 | FNTA (0.53) | SMN1; SMN2KMT2ACTSAIDO1TDO2 | |
| SCHEMBL19067137 | 0.82 | KMT2A (0.42) | SMN1; SMN2KMT2ACTSAANPEPENPEP | |
| SCHEMBL8296972 | 0.81 | KCNA5 (0.49) | SMN1; SMN2KMT2ACTSAGBA1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 391 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4702157-A1 | ACYL-TRNA SYNTHETASES | United Kingdom Research and Innovation (GB) | 2026-03-04 | — | — | EP | claimed |
| WO-2024223922-A1 | ACYL-tRNA SYNTHETASES | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2024-10-31 | — | — | WO | claimed |
| WO-2026106389-A1 | NMT INHIBITOR AND USE THEREOF | 주식회사 이노보테라퓨틱스 | 2026-05-21 | — | — | WO | disclosed |
| EP-3773573-B1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC INC (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4702156-A1 | TRNA-BASED METHODS AND RELATED COMPOSITIONS | United Kingdom Research and Innovation (GB) | 2026-03-04 | — | — | EP | disclosed |
| EP-4702157-A1 | ACYL-TRNA SYNTHETASES | United Kingdom Research and Innovation (GB) | 2026-03-04 | — | — | EP | disclosed |
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | UNIVERSITY OF CONNECTICUT (US) | 2025-12-04 | — | — | US | disclosed |
| EP-3700578-B1 | SYSTEMS FOR RENAL FUNCTION DETERMINATION | MEDIBEACON INC (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250302971-A1 | Therapeutic Nanomaterials | UNIV CONNECTICUT (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4622996-A1 | CONTROL OF NANOCAGE SELF-ASSEMBLY | King's College London (GB) | 2025-10-01 | — | — | EP | disclosed |
| US-20250229081-A1 | NANOMATERIAL COATED ELECTRODE AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT | 2025-07-17 | — | — | US | disclosed |
| EP-1621529-A1 | 3-AMINO-3-ARYLPROPIONIC ACID n-ALKYL ESTERS, PROCESS FOR PRODUCTION THEREOF, AND PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE 3-AMINO-3-ARYLPROPIONIC ACIDS AND ESTERS OF THE ANTIPODES THERETO | Ube Industries, Ltd. (JP) | 2006-02-01 | — | — | EP | disclosed |
| US-6933294-B2 | Thiophene-based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-23 | — | — | US | disclosed |
| CN-1582271-A | Inhibitors of integrin alpha v beta 6 | MERCK PATENT GMBH (DE) | 2005-02-16 | — | — | CN | disclosed |
| EP-1490371-A1 | THIOPENE-BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | Bristol-Myers Squibb Company (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20040092454-A1 | Inhibitors of integrin alphavbeta6 | MERCK PATENT GMBH (DE) | 2004-05-13 | — | — | US | disclosed |
| US-20040058930-A1 | Thiophene-based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-25 | — | — | US | disclosed |
| EP-1377540-A1 | INHIBITORS OF INTEGRIN AvB6 | MERCK PATENT GmbH (DE) | 2004-01-07 | — | — | EP | disclosed |
| WO-2003084959-A1 | THIOPENE-BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-10-16 | — | — | WO | disclosed |
| WO-2002074730-A1 | INHIBITORS OF INTEGRIN αvβ¿6? | MERCK PATENT GMBH (DE) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302971-A1 | Therapeutic Nanomaterials | TIE1, TEKT1, POLRMT | SMN1; SMN2 2104/4885KMT2A 384/4885CTSA 2973/4885 |
| US-20040058930-A1 | Thiophene-based tricyclic compounds and pharmaceutical compositions comprising same | ABCG2, PFAS, CYP2F1 | SMN1; SMN2 4802/4885KMT2A 4566/4885CTSA 925/4885 |
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | EPCAM, CD47, JAK2 | SMN1; SMN2 1218/4885KMT2A 718/4885CTSA 3353/4885 |
| US-20040092454-A1 | Inhibitors of integrin alphavbeta6 | ITGB6, ITGB1, ITGA1 | SMN1; SMN2 2913/4885KMT2A 3182/4885CTSA 2014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.